Revised: February 2018 (6th version)

Standard Commodity Classification No. of Japan
875200

■137■

- Kampo-preparation-

TSUMURA Kamikihito Extract Granules for Ethical Use

Storage
Store in light-resistant, air-tight containers.

Expiration date
Use before the expiration date indicated on the container and the outer package.

Approval No.	(61AM)3315
Date of listing in the NHI reimbursement price	October 1986
Date of initial marketing in Japan	October 1986

DESCRIPTION

Composition	7.5 g of TSUMURA Kamikihito extract granules (hereafter TJ-137) contains 5.0 g of a dried extract of the following mixed crude drugs. JP Astragalus Root ..... 3.0 g JP Bupleurum Root ..... 3.0 g JP Jujube Seed ..... 3.0 g JP Atractylodes Lancea Rhizome ….. 3.0 g JP Ginseng ..... 3.0 g JP Poria Sclerotium ..... 3.0 g JP Longan Aril ……... 3.0 g JP Polygala Root …… 2.0 g JP Gardenia Fruit …… 2.0 g JP Jujube …… 2.0 g JP Japanese Angelica Root ……. 2.0 g JP Glycyrrhiza ..... 1.0 g JP Ginger …… 1.0 g JP Saussurea Root …….. 1.0 g (JP: The Japanese Pharmacopoeia)	
	Inactive ingredients	JP Light Anhydrous Silicic Acid JP Magnesium Stearate JP Lactose Hydrate
Description	Dosage form	Granules
	Color	Light yellow-brown
	Smell	Characteristic smell
	Taste	Characteristic with slightly sweet tinge
	ID code	TSUMURA/137

INDICATIONS

TJ-137 is indicated for the relief of the following symptoms of those patients with delicate constitution and a poor complexion:

Anemia, insomnia, mental anxiety, and neurosis

DOSAGE AND ADMINISTRATION

The usual adult dose is 7.5 g/day orally in 2 or 3 divided doses before or between meals. The dosage may be adjusted according to the patient's age and body weight, and symptoms.

PRECAUTIONS

1. Careful Administration (TJ-137 should be administered with care in the following patients.)

Patients with anorexia, nausea or vomiting [These symptoms may be aggravated.]

2. Important Precautions

(1) When TJ-137 is used, the patient's "SHO" (constitution/symptoms) should be taken into account. The patient's progress should be carefully monitored, and if no improvement in symptoms/findings is observed, continuous treatment should be avoided.

(2) Since TJ-137 contains Glycyrrhiza, careful attention should be paid to the serum potassium level, blood pressure, etc., and if any abnormality is observed, administration should be discontinued.

(3) Long-term administration of a gardenia fruit-containing preparation (usually 5 years or longer) may cause mesenteric phlebosclerosis accompanied by discoloration, edema, erosion, ulceration, and stenosis of the colon. Periodical examinations such as CT scanning and colonoscopy would be desirable in cases of its long-term administration.

(4) When TJ-137 is co-administered with other Kampo-preparations (Japanese traditional herbal medicines), etc., attention should be paid to the duplication of the contained crude drugs.

SHO: The term "SHO" refers to a particular pathological status of a patient evaluated by the Kampo diagnosis, and is patterned according to the patient's constitution, symptoms, etc. Kampo-preparations (Japanese traditional herbal medicines) should be used after confirmation that it is suitable for the identified "SHO" of the patient.

3. Drug Interactions

Precautions for coadministration (TJ-137 should be administered with care when coadministered with the following drugs.)

Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors
(1) Preparations containing Glycyrrhiza (2) Preparations containing glycyrrhizinic acid or glycyrrhizinates	Pseudoaldosteronism is likely to occur. Besides, myopathy is likely to occur as a result of hypokalemia. (Refer to the section "Clinically significant adverse reactions".)	Since glycyrrhizinic acid has an accelerating action on the potassium excretion at the renal tubules, an acceleration of decrease in the serum potassium level has been suggested.

4. Adverse Reactions

TJ-137 has not been investigated (drug use investigations, etc.) to determine the incidence of adverse reactions. Therefore, the incidence of adverse reactions is not known.

(1) Clinically significant adverse reactions

1) Pseudoaldosteronism: Pseudoaldosteronism such as hypokalemia, increased blood pressure, retention of sodium/body fluid, edema, increased body weight, etc. may occur. The patient should be carefully monitored (measurement of serum potassium level, etc.), and if any abnormality is observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken.

2) Myopathy: Myopathy may occur as a result of hypokalemia. The patient should be carefully monitored, and if any abnormality such as weakness, convulsion/paralysis of limbs, etc. are observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken.

3) Mesenteric phlebosclerosis: Mesenteric phlebosclerosis may occur with long-term administration. If symptoms such as abdominal pain, diarrhea, constipation, and abdominal distension repeatedly occur, or if the patient tests positive for fecal occult blood, administration should be discontinued. At the same time, tests such as CT and colonoscopy should be performed, and appropriate measures should be taken. Intestinal resection has been reported in some cases.

(2) Other adverse reactions

	Incidence unknown
Hypersensitivity Note1)	Rash, Urticaria, etc.
Gastrointestinal	Anorexia, Epigastric distress, Nausea, Abdominal pain, Diarrhea, etc.

Note 1) If such symptoms are observed, administration should be discontinued.

5. Use in the Elderly

Because elderly patients often have reduced physiological function, careful supervision and measures such as reducing the dose are recommended.

6. Use during Pregnancy, Delivery or Lactation

The safety of TJ-137 in pregnant women has not been established. Therefore, TJ-137 should be used in pregnant women, women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment.

7. Pediatric Use

The safety of TJ-137 in children has not been established. [Insufficient clinical data]

8. Effects on Laboratory Tests

Treatment with TJ-137 may cause an increase in blood AG (1, 5-anhydro-D-glusitol) level.

9. Other Precautions

Eczema, dermatitis, etc. may be aggravated.

PHARMACOLOGY

Anxiolytic-like activity

Oral administration of Kamikihito to mice showed anxiolytic-like actions in an improved elevated plus maze[1].

PACKAGING

Bottles of 500 g
2.5 g × 42 packets
2.5 g × 189 packets

REFERENCES

1) Kurihara, H. et al. Jpn. J. Neuropsychopharmacol. 1996, 18(3), p.179.

REQUEST FOR LITERATURE SHOULD BE MADE TO:
Consumer Information Services Center
Tsumura & Co.
2-17-11 Akasaka, Minato-ku, Tokyo 107-8521, Japan
TEL:0120-329970 FAX:03-5574-6610

Manufactured and Distributed by:
Tsumura & Co.
2-17-11 Akasaka, Minato-ku, Tokyo 107-8521, Japan